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estagen treatment enhances the tocolytic effect of salmeterol
n hormone-induced preterm labor in the rat in vivo
árta Gálik; Róbert Gáspár, PhD; Zoltán Kolarovszki-Sipiczki, PhD; George Falkay, DScBJECTIVE: The purpose of this study was to determine whether ge-
tagen treatment enhances the effects of 2-mimetics in hormone-in-
uced preterm delivery in pregnant rats in vivo.
TUDY DESIGN: Preterm birth was induced with a combination of
ifepristone and prostaglandin E2 on day 19 of pregnancy. The ani-
als were treated with salmeterol or gestagens (progesterone or 17-
ydroxyprogesterone) or their combination. The treatments were
aunched on different days (15-18) of pregnancy. The efficacy of treat-
ent was determined in terms of the delivery time counted from therectives (86/609/ECC)
oi: 10.1016/j.ajog.2007.09.027ESULTS: Salmeterol treatment delayed premature labor by 2.4 hours,
hereas the delay because of the gestagen-salmeterol combinations
as more than 5 hours. Progesterone had no effect on the delivery
ime.
ONCLUSION: Parallel treatment with salmeterol and gestagens can be
ore than twice as effective as salmeterol therapy alone. These results
pen up a possibility for human trials of combined 2-agonist–gesta-
en therapy in threatening preterm delivery.ifepristone injection. Key words: beta-mimetics, gestagens, preterm birth, rat, tocolysis
ite this article as: Gálik M, Gáspár R, Kolarovszki-Sipiczki Z, et al. Gestagen treatment enhances the tocolytic effect of salmeterol in hormone-induced
reterm labor in the rat in vivo. Am J Obstet Gynecol 2008;198:319.e1-319.e5.
arious medications have been used
in tocolytic therapy, but none have
een established as effective treatment of
reterm labor. Supplemental treatment
ith progesterone (P) has been studied
o prevent preterm labor and birth1-4
nd as an adjunct to treat acute preterm
abor.5 It has been shown to reduce the
isk of recurrent preterm birth when
sed prophylactically but has not been
horoughly investigated as an adjunct to
ocolytic drugs. Erny et al6 found that
ral P reduced uterine activity, com-
ared with placebo, in a randomized
omparison in 57 women admitted with
isk of preterm labor. Noblot et al5 found
hat the addition of micronized P to
-mimetic treatment reduced uterine
activity more quickly than -mimetic
treatment alone, but there was no effect
on the prolongation of pregnancy.
It is known that P increases 2-adren-
ergic receptor (AR) expression during
pregnancy,7 and P can alter the effects of
2-AR agonists on the pregnant myome-
trium.8 Gáspár et al9 demonstrated that
in vivo P treatment can favorably affect
the level of the 2-ARs and also enhance
the uterus-relaxing effect of terbutaline
in vitro. Chanrachakul et al10 found that
in vitro P increased the uterus-relaxing
effect of ritodrine by reducing 50% of
the maximal response, amplitude, and
frequency of the myometrial contrac-
tions in the isolated human pregnant
myometrium.
The efficacy of the gestagen-2-ago-
nist combination has not been ade-
quately investigated in vivo. In the
present study, we sought an answer as to
whether gestagen treatment increases
the effects of 2-mimetics in hormone-
induced preterm delivery in rats in vivo.
MATERIAL AND METHODS
Housing and handling
of the animals
The animals were treated according to
the European Communities Council Di-
ian Act for the Protection of Animals in
Research (XXVIII.tv.32.§). All experi-
ments involving animal subjects were
carried out with the approval of the
Hungarian Ethical Committee for Ani-
mal Research (registration IV/1813-1/
2002). Sprague-Dawley rats (Charles
River Laboratories, Hungary) were kept
at 22  3°C; the relative humidity was
30-70% and the light/dark cycle was 12
hours/12 hours. They were maintained
on a standard rodent pellet diet (Charles
River Laboratories), with tap water avail-
able ad libitum.
Mating of the animals
Mature female (180-200 g) and male
(240-260 g) Sprague-Dawley rats were
mated in a special mating cage. Vaginal
smears were taken from the female rats
and a sperm search was performed under
a microscope at a magnification of
1200. If the smear proved positive, the
female rats were separated and were re-
garded as first-day pregnant animals.
Induction of premature labor
Preterm labor was induced according to
Rechberger et al.11 Briefly, the animals
were treated with mifepristone (3 mg per
0.1 mL) and prostaglandin E2 (PGE2; 0.5
rom the Department of
harmacodynamics and Biopharmacy,
aculty of Pharmacy, University of Szeged,
zeged, Hungary.
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3hich may approximately correlate to
he gestation weeks 34-35 if we consider
hat the duration of pregnancy is 22 and
FIGURE 1
Time schedule of treatments and
of hormone-induced preterm birth
A
Conception Initiation
Day 1    D
Group A:    - 
Group B P
Group C    -
Group D P
Group E    17
     
Day 15 Day 16 Day 17 
Group A   -       -        - 
Group B   P P P
Group C    S S   S
Group D   P S P S P S
Group E 17P S 17P S  17P S
he time schedule of the treatments and the initia
ats treated from day 15. A, Time schedule fr
almeterol/gestagen treatments were started on
reatments were initiated later in pregnancy (on
nitiation of induction were the same, implicitl
almeterol-gestagen to the preterm birth. When
ater in pregnancy (day 16, 17, or 18), the animal
mplicitly. 17P, 17-hydroxyprogesterone capro
irth; PG, prostaglandin E2; S, salmeterol.
álik. Gestagen treatment enhances tocolytic effect of salmete
ynecol 2008.80 days in rat and human, respectively. i
19.e2 American Journal of Obstetrics & Gynecolifepristone was suspended in olive oil
nd given as a subcutaneous injection at
:00 A.M. At 4:00 P.M, PGE2 was applied
iation
Treatments Initiation of Induction 
5   Day 19
-
- 
S
S
 S
Initiation    PB 
  of PB
Day 18 Day 19 Day 20 
     -   M PG      - 
P   M PG   P
P
  S   M PG    S
S
P S    M PG    P S
P S
17P S    M PG  17P S
7P S
n of hormone-induced preterm birth in pregnant
conception to initiation of preterm birth. The
15 in this case. When the salmeterol-gestagen
y 16, 17, or 18), the days of conception and
, Time schedule from the first treatment with
salmeterol-gestagen treatments were initiated
d not receive any treatments on the earlier days,
M, mifepristone; P, progesterone; PB, preterm
n hormone-induced preterm labor in rat. Am J Obstetntravaginally. The delivery time of the t
ogy MARCH 2008rst fetus was noted as the duration in
ours from the time of mifepristone
dministration.
reatments of the animals
almeterol xinafoate (Sigma Aldrich,
udapest, Hungary) was dissolved in a
:1 methanol-water mixture. Alzet os-
otic pumps (model 2ml1; DURECT
orp, Cupertino, CA) loaded with sal-
eterol xinafoate solution or the vehicle
as inserted subcutaneously into the
ack skin of rats on days 15-18 of preg-
ancy (which may correlate to gestation
eeks 27-35 in humans) under isoflu-
ane anesthesia (Burton’s narcotic appa-
atus). The dose of salmeterol was 130
g/day per animal. Pefloxacin was used
n dose of 8 mg per 0.1 mL/animal to
revent subsequent infections.
P (Sigma Aldrich) or 17-hy-
roxyprogesterone caproate (17P; do-
ated by Richter Gedeon NyRt, Budap-
st, Hungary) was suspended in olive oil
nd was injected subcutaneously in a
ose of 0.5 mg per 0.1 mL/day from days
f pump insertions to day 20 of preg-
ancy. The time schedule of the animal
reatments is shown on Figure 1.
xperimental design
roup A was the control group, and
roup B was treated with P, group C with
almeterol, group D with the combina-
ion of salmeterol and P, and group E
ith the combination of salmeterol and
7P. Eight rats were in each group. All
he animals were operated on for os-
otic minipump insertion and were
reated with subcutaneous injections.
he osmotic minipumps contained sal-
eterol or vehicle, and the subcutaneous
njection contained gestagens or the
ehicle.
The salmeterol/gestagen/vehicle treat-
ents started on different days (15, 16,
7, or 18) of pregnancy, with the excep-
ion of the animals in group E, in which
he treatment always started on pregnant
ay 15.
Statistical analysis was carried out with
he analysis of variance Newman-Keulsinit
 of 
ay 1
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n group A (control), preterm labor oc-
urred within 24 hours after mifepristone
reatment, at about 9:00 A.M. on pregnancy
ay 20 (which may correlate to the 36th
eek of pregnancy in humans).
Group B (P) treatment started on
FIGURE 2
Effects of P, salmeterol, and
combined gestagen-salmeterol
treatments started on gestation
day 15 on hormone-induced
preterm delivery
he effects of progesterone (0.5 mg per 0.1 mL),
almeterol (130 g/day), and combined gesta-
en-salmeterol treatments on hormone-induced
reterm delivery in the rat (n  8 for each
roup). The treatments were started on gestation
ay 15. A, A, control group; B, P-treated; C,
almeterol-treated; D, salmeterol–P combina-
ion-treated; E, salmeterol-17-hydroxyproges-
erone caproate combination-treated animals.
he bar graphs show means SEM. The effects
ere compared with the results on the control
roup. ns, not significant. Asterisk indicates P
.05; double asterisks indicate P  .01; triple
sterisks indicate P  .001. The difference in
fficacy between the treatments reflected in
roups C and D was significant (P  .01). The
roup E combination was as effective as the
roup D combination (P  .05). B, Time to
elivery from the initiation of preterm birth
mifepristone treatment). The longest delay was
aused by the combination of salmeterol-pro-
esterone (5.2 hours).
álik. Gestagen treatment enhances tocolytic effect of
almeterol in hormone-induced preterm labor in rat. Am J
bstet Gynecol 2008.regnancy day 15 and was not effective tn delaying the hormone-induced pre-
erm delivery. In contrast, in group C
salmeterol), the treatment was effective;
remature birth was delayed by 2.4
ours. The group D (salmeterol–P com-
ination) delayed labor by 5.2 hours
Figure 2).
The results were similar when the
reatments started on days 16-18 of preg-
ancy (Figures 3-5). In each case, group
and group E (combined therapy) was
ore effective than group B and C (sim-
le treatment). The difference in efficacy
etween groups C and D was most ex-
ressed for the treatment started on day
5 (Figure 2).
In group E, the preterm birth– delay-
ng effect of salmeterol-17P treatment
as very similar to that of the salmet-
rol–P combination. The difference be-
ween the 2 combinations was not signif-
cant (Figure 2).
OMMENT
hanrachakul et al10 investigated the ef-
ects of in vitro P and ritodrine on oxy-
ocin-induced human myometrial con-
ractility. They reported that P
ignificantly enhances the relaxant effect
f the 2-mimetic by reducing both the
mplitude and the frequency of the con-
ractions. These previous results led us to
est the efficacy of salmeterol-gestagens
P and 17P) treatment in hormone-in-
uced preterm delivery in rat in vivo. We
sed the same in vivo P dose that had
roved effective in increasing the effect
f the 2-agonist in our earlier study.
9
n in vivo dose for the tocolytic effect of
almeterol was not available for the rat;
e therefore chose the dose used by
oore et al.12 This dose was able to in-
uce muscular growth in the rat, indicat-
ng the systemic effect of the drug.12
Interestingly, although delivery did re-
ult from the P antagonist mifepristone
n combination with PGE2, the gestagen
reatment did not prevent the hormone-
nduced premature labor. Salmeterol
reatment was effective in delaying pre-
erm labor, and this effect was doubled
y its combination with gestagens, inde-
endently of the first day of treatment:
ven 1 day of gestagen treatment before
he administration of mifepristone and s
MARCH 2008 AmericaGE2 potentiated the effect of salmet-
rol. This result means that the enhanced
ynergistic effect of gestagens can de-
elop rapidly. The improved efficacy of
he combination can very probably be
xplained by the gestagen-induced in-
reases in the myometrial 2-AR density
nd the amount of activated G proteins
oupled to -ARs, as found earlier.9
It should be emphasized that there are
FIGURE 3
Effects of P, salmeterol, and
combined P-salmeterol
treatments started on gestation
day 16 on hormone-induced
preterm delivery
he effects of P (0.5 mg per 0.1 mL), salmeterol
130 g/day), and combined P-salmeterol treat-
ents on hormone-induced preterm delivery in
he rat (n  8 for each group). The treatments
ere started on gestation day 16. A, A, control
roup; B, P-treated animals; C, salmeterol-
reated animals; D, salmeterol–P combination-
reated animals. The bar graphs show means 
EM. The effects were compared with the results
n the control group. ns, not significant. Aster-
sk indicates p  .05; double asterisks indicate
 .01; triple asterisks indicate P .001. The
ifference in efficacy between the treatments
eflected in groups C and D was significant (P
.05). B, Time to delivery from the initiation of
reterm birth (mifepristone treatment). The long-
st delay was caused by the combination of
almeterol-progesterone (4.5 hours).
álik. Gestagen treatment enhances tocolytic effect of
almeterol in hormone-induced preterm labor in rat. Am J
bstet Gynecol 2008.ome limitations of our study. We at-
n Journal of Obstetrics & Gynecology 319.e3
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3empted to demonstrate the effects of
hese compounds on a lipopolysaccha-
ide (LPS)-induced preterm labor
odel, which is widely accepted as an
ppropriate animal test for human pre-
erm birth. Unfortunately, we have not
een able to construct an LPS model
ith good reproducibility. The majority
f the pregnant rats were not able to de-
iver the fetuses: frequent intrauterine
FIGURE 4
Effects of P, salmeterol, and
combined P-salmeterol
treatments started on gestation
day 17 on hormone-induced
preterm delivery
he effects of P (0.5 mg per 0.1 mL), salmeterol
130 g/day), and combined P-salmeterol treat-
ents on hormone-induced preterm delivery in
he rat (n  8 for each group). The treatments
ere started on gestation day 17. A, control
roup; B, P-treated animals; C, salmeterol-
reated animals; D, salmeterol–P combination-
reated animals. The bar graphs show means 
EM. The effects were compared with the results
n the control group. ns, not significant. Aster-
sk indicates P  .05; double asterisks indicate
 .01; triple asterisks indicate P .001. The
ifference in efficacy between the treatments
eflected in groups C and D was significant (P
.05). B, Time to delivery from the initiation of
reterm birth (mifepristone treatment). The long-
st delay was caused by the combination of
almeterol-P (4.3 hours).
álik. Gestagen treatment enhances tocolytic effect of
almeterol in hormone-induced preterm labor in rat. Am J
bstet Gynecol 2008.eaths occurred, as described earlier.13 f
19.e4 American Journal of Obstetrics & Gynecolerrone et al14 reported results on LPS-
nduced preterm birth with rats, but in
hose experiments the LPS-induced de-
ivery occurred 92 hours after the initia-
ion of the process and the live birth rate
as only around 50%. The LPS-induced
elivery could be delayed by 26-29 hours
ith parallel or preventive interleukin
reatment.14
A comparison of the LPS- and the hor-
one-induced models clearly reveals
hat the process of LPS-induced delivery
s slower, and therefore, there may be a
reater chance of reaching a longer pro-
ongation of the whole process than in
he case of hormone-induced preterm
irth, in which the process is drastic and
as been completed within 24 hours. Ac-
ordingly, the more than 5-hour delay in
he hormone-induced model should be
egarded as a significant and promising
ffect of the combinations of salmeterol
nd the gestagen compounds.
Another weakness of this study is that
he experiments do not provide any data
bout the prompt effect of the drugs in
he onset of the hormone-induced pre-
erm birth, but the investigation of a
rompt effect is almost impossible in
ats. The first visual sign of the onset of
abor is vaginal bleeding. From this time
n, we have a maximum of only 10-15
inutes (frequently much less) until the
elivery of the first fetus. This short pe-
iod is surely not enough for the absorp-
ion of drugs administered extravasally,
hereas intravenous administration is
ot appropriate for the gestagens. Addi-
ionally, the osmotic minipump is not
eally suitable for fast treatment. Never-
heless, in spite of all these weaknesses,
ur study is the first in which an attempt
s made to delay the antigestagen-prosta-
landin-induced preterm birth in vivo.
The fact that the gestagens potentiate
he uterus-relaxing effect of2-mimetics
ay yield a possibility for avoiding or di-
inishing the overuse of 2-agonists
nd the pregnancy-induced desensitiza-
ion of 2-ARs.
9,15,16
We conclude that a putative therapeutic
ombination of a 2-AR agonist and a ge-
tagen compound may enhance the effi-
acy of human tocolytic therapy. Although
t is very difficult to transpose such a result
rom an animal study into human practice, p
ogy MARCH 2008e presume that the delay of more than 5
ours caused by the salmeterol-gestagen in
at preterm delivery is very promising for
uman trials. If we consider that both 2-
imetics and gestagens are well known
ith regard to their pharmacokinetics and
oxicity, the expected therapeutic risk of
heir combination is relatively low. In view
f all the preclinical results and earlier ex-
FIGURE 5
Effects of P, salmeterol, and
combined P-salmeterol
treatments started on gestation
day 18 on hormone-induced
preterm delivery
he effects of progesterone (0.5 mg per 0.1 mL),
almeterol (130 g/day), and combined P-sal-
eterol treatments on the hormone-induced
reterm delivery in the rat (n  8 for each
roup). The treatments were started on gestation
ay 18. A, A, control group; B, P-treated ani-
als; C, salmeterol-treated animals; D, salmet-
rol–P combination-treated animals. The bar
raphs show means  SEM. The effects were
ompared with the results on the control group.
s, not significant. Asterisk indicates P  .05;
ouble asterisks indicate P  .01; triple aster-
sks indicate P .001. The difference in efficacy
etween the treatments reflected in groups C
nd D was significant (P  .05). B, Time to
elivery from the initiation of preterm birth
mifepristone treatment). The longest delay was
aused by the combination of salmeterol-P (5.8
ours).
álik. Gestagen treatment enhances tocolytic effect of
almeterol in hormone-induced preterm labor in rat. Am J
bstet Gynecol 2008.erience with the drugs, we think that
t
p
g
T
c
h
A
S
R
t
R
1
o
t
1
2
p
O
3
r
d
2
4
p
v
s
i
t
n
5
m
m
n
6
o
t
1
7
m
s
P
8
c
t
v
9
i
b
r
R
1
P
r
1
J
o
f
s
1
e
e
A
1
p
2
1
t
t
s
1
f
s
p
s
b
5
1
s
c
a
www.AJOG.org Basic Science: Obstetrics Researchhere is sufficient evidence indicative of the
otentiation of the 2-mimetic effect by
estagens in pregnant uterine relaxation.
he time may have come to begin trials to
larify the effects of such a combination in
uman preterm birth. f
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